Jeremy G. Chadwick net worth and biography

Jeremy Chadwick Biography and Net Worth

Prior to Kymera, Dr. Chadwick served as Senior Vice President, Head of Global Development Office at Takeda Pharmaceuticals. During his time there, he headed Regulatory Affairs, as well as managed Development Operations, Drug Safety and Clinical Supply Chain . Before Takeda, Dr. Chadwick was Group Vice President and Head of Clinical Development Operations at Shire Pharmaceuticals. Earlier in his career, Dr. Chadwick held a number of senior development roles with broad responsibilities including program management, development operations, regulatory affairs, drug safety, biostatistics and data management, working in The Medicines Company, Synta Pharmaceuticals, Vertex Pharmaceuticals, Parexel International and Glaxo Group Research. Dr. Chadwick has been involved in multiple successful global approvals across numerous therapeutic areas. Dr. Chadwick previously served as chairman of the Board of Directors at Accumulus Synergy, who are leading the charge to develop transformative data exchange platform designed to enhance how biopharmaceutical innovators and regulators bring safe and effective medicines to patients faster. He earned his MS and PhD in Statistics from the University of London and a BS in Mathematics from Demontfort University in the UK.

What is Jeremy G. Chadwick's net worth?: The estimated net worth of Jeremy G. Chadwick is at least $5.44 million as of April 1st, 2026. Dr. Chadwick owns 61,202 shares of Kymera Therapeutics stock worth more than $5,442,633 as of April 15th. This net worth approximation does not reflect any other assets that Dr. Chadwick may own. Learn More about Jeremy G. Chadwick's net worth.
How do I contact Jeremy G. Chadwick?: The corporate mailing address for Dr. Chadwick and other Kymera Therapeutics executives is 200 Arsenal Yards Blvd. Suite 230, Watertown MA, 02472. Kymera Therapeutics can also be reached via phone at 857-285-5300 and via email at [email protected]. Learn More on Jeremy G. Chadwick's contact information.
Has Jeremy G. Chadwick been buying or selling shares of Kymera Therapeutics?: During the last quarter, Jeremy G. Chadwick has sold $1,251,134.40 in shares of Kymera Therapeutics stock. Most recently, Jeremy G. Chadwick sold 14,640 shares of the business's stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $85.46, for a transaction totalling $1,251,134.40. Following the completion of the sale, the chief operating officer now directly owns 61,202 shares of the company's stock, valued at $5,230,322.92. Learn More on Jeremy G. Chadwick's trading history.
Who are Kymera Therapeutics' active insiders?: Kymera Therapeutics' insider roster includes Jeffrey Albers (Director), Bruce Booth (Director), Jeremy Chadwick (COO), Richard Chesworth (Insider), Ellen Chiniara (Chief Legal Officer and Corporate Secretary), Jared Gollob (Insider), Noah Goodman (Chief Business Officer), Bruce Jacobs (CFO), Nello Mainolfi (CEO), and Elena Ridloff (Director). Learn More on Kymera Therapeutics' active insiders.
Are insiders buying or selling shares of Kymera Therapeutics?: In the last twelve months, Kymera Therapeutics insiders bought shares 3 times. They purchased a total of 2,978,480 shares worth more than $215,297,266.00. In the last twelve months, insiders at the sold shares 33 times. They sold a total of 1,003,196 shares worth more than $79,141,671.17. The most recent insider tranaction occured on April, 10th when insider Noah Goodman sold 2,000 shares worth more than $174,700.00. Insiders at Kymera Therapeutics own 16.0% of the company. Learn More about insider trades at Kymera Therapeutics.
Information on this page was last updated on 4/10/2026.

Jeremy G. Chadwick Insider Trading History at Kymera Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/1/2026	Sell	14,640	$85.46	$1,251,134.40	61,202
3/31/2026	Sell	7,600	$85.38	$648,888.00	61,202
3/25/2026	Sell	24,727	$80.26	$1,984,589.02	61,202
3/23/2026	Sell	91,250	$77.41	$7,063,662.50	61,202
3/11/2026	Sell	25,758	$83.30	$2,145,641.40	68,052
3/4/2026	Sell	3,919	$85.30	$334,290.70	73,810
3/2/2026	Sell	2,039	$88.93	$181,328.27	77,729
3/3/2025	Sell	1,383	$30.45	$42,112.35	67,800

Jeremy G. Chadwick Buying and Selling Activity at Kymera Therapeutics

Kymera Therapeutics Company Overview

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Today's Range

Now: $88.93

$89.55

$89.97

50 Day Range

MA: $83.46

$74.42

$95.03

2 Week Range

Now: $88.93

$24.42

$103.00

Volume

11,362 shs

Average Volume

729,648 shs

Market Capitalization

$7.26 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.28